Sartorius Stedim Biotech Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St · 10/18 04:13

Sartorius Stedim Biotech (EPA:DIM) Third Quarter 2024 Results

Key Financial Results

  • Revenue: €655.4m (down 1.7% from 3Q 2023).
  • Net income: €25.5m (flat on 3Q 2023).
  • Profit margin: 3.9% (in line with 3Q 2023).
  • EPS: €0.26 (down from €0.28 in 3Q 2023).
earnings-and-revenue-growth
ENXTPA:DIM Earnings and Revenue Growth October 18th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sartorius Stedim Biotech Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 4.9%. Earnings per share (EPS) also missed analyst estimates by 52%.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.

Performance of the market in France.

The company's shares are up 12% from a week ago.

Risk Analysis

You should learn about the 5 warning signs we've spotted with Sartorius Stedim Biotech (including 1 which makes us a bit uncomfortable).